CUSIP: 16961L106
Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
53,190,947
-
Share change
-
+9,025,444
-
Total reported value
-
$930,308,485
-
Price per share
-
$17.49
-
Number of holders
-
131
-
Value change
-
+$160,072,921
-
Number of buys
-
96
-
Number of sells
-
35
Quarterly Holders Quick Answers
What is CUSIP 16961L106?
CUSIP 16961L106 identifies KDNY - CHINOOK THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2022
-
Previous quarter:
Q1 2022
Recent filing periods for CUSIP 16961L106:
Institutional Holders of CHINOOK THERAPEUTICS INC - COM (KDNY) as of Q2 2022
As of 30 Jun 2022,
CHINOOK THERAPEUTICS INC - COM (KDNY) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,190,947 shares.
The largest 10 holders included
Samsara BioCapital, LLC, Frazier Life Sciences Management, L.P., Deep Track Capital, LP, BlackRock Inc., Octagon Capital Advisors LP, BAKER BROS. ADVISORS LP, Point72 Asset Management, L.P., VANGUARD GROUP INC, ORBIMED ADVISORS LLC, and SUVRETTA CAPITAL MANAGEMENT, LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.